Workflow
Apyx Medical(APYX)
icon
Search documents
Apyx Medical(APYX) - 2023 Q4 - Annual Report
2024-03-21 16:08
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each Class Trading Symbol Name of each Exchange on which registered Common Stock, $0.001 Par Value APYX Nasdaq Global Select Market FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Nu ...
Apyx Medical(APYX) - 2023 Q4 - Earnings Call Transcript
2024-03-21 14:12
Apyx Medical Corporation (NASDAQ:APYX) Q4 2023 Earnings Conference Call March 21, 2024 8:00 AM ET Company Participants Charles D. Goodwin - President & CEO Matt Hill - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets George Sellers - Stephens Inc. Matthew Hewitt - Craig-Hallum Capital Group Unidentified Analyst - Piper Sandler David Turkaly - JMP Securities Operator Hello, and welcome, ladies and gentlemen to the Fourth Quarter and Fiscal Year 2023 Earnings Conference Call for A ...
Apyx Medical (APYX) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research· 2024-03-21 13:15
Apyx Medical (APYX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -46.15%. A quarter ago, it was expected that this medical device maker would post a loss of $0.10 per share when it actually produced a loss of $0.13, delivering a surprise of -30%.Over the last four quarters, the company has ...
Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2023 Financial Results on March 21, 2024
Businesswire· 2024-03-04 12:30
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx® Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the fourth quarter and fiscal year 2023 will be released before the market opens on Thursday, March 21st. Management will host a conference call at 8:00 a.m. Eastern Time on March 21st to discuss the results of the quarter and year, and to host a question and answer ...
Apyx Medical Corporation Announces Renuvion to be Featured in Educational Sessions at the American Academy of Cosmetic Surgery (AACS) Scientific Meeting
Businesswire· 2024-02-21 12:30
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (Nasdaq: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that its Renuvion technology will be featured in three educational sessions at the upcoming American Academy of Cosmetic Surgery’s 40th Annual Scientific Meeting, to be held in New Orleans, LA from February 22 – 24. “ Apyx Medical is pleased to see Renuvion featured in a varie ...
Apyx Medical Corporation Announces Peer-Reviewed Clinical Publication Evaluating the Safety of Renuvion® Following Liposuction in Multiple Areas of the Body
Businesswire· 2024-01-22 12:30
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (Nasdaq: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the publication of a peer-reviewed article in the Aesthetic Surgery Journal Open Forum, which evaluated the use of Renuvion for contracting subcutaneous soft tissue following liposuction in multiple areas of the body. “ We are excited to see the publication of this real-world ...
Apyx Medical(APYX) - 2023 Q3 - Quarterly Report
2023-11-09 20:49
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock APYX Nasdaq Stock Market, LLC FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001 ...
Apyx Medical(APYX) - 2023 Q3 - Earnings Call Transcript
2023-11-09 16:30
Apyx Medical Corporation (NASDAQ:APYX) Q3 2023 Earnings Conference Call November 9, 2023 8:00 AM ET Company Participants Charles Goodwin - President & CEO Tara Semb - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Matthew O'Brien - Piper Sandler Matt Hewitt - Craig-Hallum George Sellers - Stephens Dave Turkaly - JMP Securities Operator Please stand by. Hello, and welcome, ladies and gentlemen, to the Third Quarter of Fiscal Year 2023 Earnings Conference Call for Apyx Medical C ...
Apyx Medical(APYX) - 2023 Q2 - Earnings Call Transcript
2023-08-12 16:09
Apyx Medical Corporation (NASDAQ:APYX) Q2 2023 Earnings Conference Call August 1, 2023 5:00 PM ET Company Participants Charles Goodwin - President & CEO Tara Semb - CFO Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group George Sellers - Stephens Frank Takkinen - Lake Street Capital Markets Operator Hello, and welcome, ladies and gentlemen, to the Second Quarter of Fiscal 2023 Earnings Conference Call for Apyx Medical Corporation. At this time, all participants have been placed in a listen ...
Apyx Medical(APYX) - 2023 Q2 - Quarterly Report
2023-08-10 21:46
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock APYX Nasdaq Stock Market, LLC FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 0-12183 ...